PA
GIW

PharVision Advisers’s GigCapital8 GIW Stock Holding History

PharVision Advisers’s Portfolio GIW Stock Details GIW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,607
Closed -$164K – 706
2025
Q4 		$164K Buy
+16,607
New +$165K 0.08% 602

Other funds holding GIW

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
TCM
Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.1B AUM 13.6% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $7.65B AUM 14.02% 1-Year Est. Return

PharVision Advisers's GIW Position: Q1 2026 in Review

PharVision Advisers sold out of GigCapital8 (GIW) in Q1 2026, closing a stake of 16,607 shares — an estimated $164K sold.

PharVision Advisers first reported a position in GIW in Q4 2025 and held it in 1 quarter. The position peaked at $164K in Q4 2025. 53 funds tracked by Wall St. Rank hold GIW as of Q1 2026.

  • PharVision Advisers reported no remaining GigCapital8 position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 16,607 GigCapital8 shares in Q1 2026, an estimated $164K.
  • PharVision Advisers first reported a position in GigCapital8 in Q4 2025 and held it in 1 quarter.
  • PharVision Advisers's GigCapital8 position peaked at $164K in Q4 2025.
  • 53 funds tracked by Wall St. Rank held GigCapital8 as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.